Education
About Us
Working with TipRanks
Follow Us
Inozyme Pharma (INZY)
NASDAQ:INZY
Total Valuation
Inozyme Pharma has a market cap or net worth of $62.26M. The enterprise value is $246.12M.
Market Cap$62.26M
Enterprise Value$246.12M
Share Statistics
Inozyme Pharma has 64.24M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64.24M
Owned by Insiders2.99%
Owned by Instutions54.56%
Financial Efficiency
Inozyme Pharma’s return on equity (ROE) is -1.76 and return on invested capital (ROIC) is -99.36%.
Return on Equity (ROE)-176.43%
Return on Assets (ROA)-82.82%
Return on Invested Capital (ROIC)-99.36%
Return on Capital Employed (ROCE)-116.52%
Revenue Per Employee$0
Profits Per Employee-$1,522,746.269
Employee Count67
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inozyme Pharma is -1.71. Inozyme Pharma’s PEG ratio is -0.09.
PE Ratio-1.71
PS Ratio0.00
PB Ratio3.01
Price to Fair Value3.01
Price to FCF-1.89
Price to Operating Cash Flow-1.89
PEG Ratio-0.09
Income Statement
In the last 12 months, Inozyme Pharma had revenue of $0.00 and earned -$102.02M in profits. Earnings per share was -$1.64.
Revenue$0.00
Gross Profit-$565.00K
Operating Income-$104.03M
Pretax Income-$102.02M
Net Income-$102.02M
EBITDA-95.72M
Earnings Per Share (EPS)-1.64
Cash Flow
In the last 12 months, operating cash flow was -$91.91M and capital expenditures -$62.00K, giving a free cash flow of -$91.97M billion.
Operating Cash Flow-$91.91M
Free Cash Flow-$91.97M
Free Cash Flow per Share-$1.43
Dividends & Yields
Inozyme Pharma pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-52.86%
Earnings Yield-58.64%
Stock Price Statistics
Beta1.70
52-Week Price Change-78.49%
50-Day Moving Average1.11
200-Day Moving Average3.37
Relative Strength Index (RSI)50.85
Average Volume (3m)501.12K
Important Dates
Inozyme Pharma upcoming earnings date is May 13, 2025, Before Open.
Last Earnings DateMar 10, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Inozyme Pharma as a current ratio of 3.56, with Debt / Equity ratio of 0.27
Current Ratio3.56
Quick Ratio3.56
Debt to Market Cap0.09
Net Debt to EBITDA0.05
Interest Coverage Ratio18.72
Taxes
In the past 12 months, Inozyme Pharma has paid -$182.00K in taxes.
Income Tax-$182.00K
Effective Tax Rate0.00%
Enterprise Valuation
Inozyme Pharma EV to EBITDA ratio is -1.62, with an EV/FCF ratio of -1.83.
EV to Sales0.00
EV to EBITDA-1.62
EV to Free Cash Flow-1.83
EV to Operating Cash Flow-1.83
Balance Sheet
Inozyme Pharma has $113.09M in cash and marketable securities with $46.87M in debt, giving a net cash position of -$66.21M billion.
Cash & Marketable Securities$113.09M
Total Debt$46.87M
Net Cash-$66.21M
Net Cash Per Share-$1.03
Tangible Book Value Per Share$0.92
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Inozyme Pharma is $13.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.29
Price Target Upside1229.00%
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast
EPS Growth Forecast-17.06%